Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.
Actively Recruiting
Researchers are evaluating whether eptinezumab can reduce the number of migraine days in children and adolescents aged 6 to 17 with episodic migraine. The study aims to assess the safety and effectiveness of intravenous eptinezumab in preventing episodic migraine in this pediatric population. Participants are assigned randomly to receive one of three treatments a single intravenous infusion of eptinezumab 300 mg adjusted for weight, a single intravenous infusion of eptinezumab 100 mg adjusted for weight, or a matching placebo infusion. The study is double-blind and uses a parallel-group design to compare these treatments. During the 12 weeks following dosing, participants will complete headache diaries and undergo assessments including migraine frequency, headache days, medication use, pain intensity, and quality of life measures like the Pediatric Migraine Disability Assessment. Blood samples will be collected at several points to measure eptinezumab levels and antibodies. Safety and treatment responses are monitored throughout the study period.
Actively Recruiting
Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.
Actively Recruiting
Researchers are evaluating eptinezumab to see if it reduces the number of migraine days compared to a placebo in young people aged 12 to 17 with chronic migraine. This phase 3 study focuses on adolescents who have had chronic migraine for at least six months and aims to assess the preventive treatment effects of this intravenous drug. Participants are randomly assigned to one of three groups to receive a single intravenous infusion of either eptinezumab 300 mg, eptinezumab 100 mg, or a placebo. The doses are adjusted according to each participants body weight. The study includes a 4-week screening period, followed by a 12-week double-blind treatment phase, and ends with an 8-week safety follow-up period. During the study, participants will complete headache diaries and undergo evaluations to measure changes in monthly migraine days and other migraine-related outcomes. Researchers will also monitor blood levels of eptinezumab and immune responses. The total study participation lasts approximately 24 weeks, including screening, treatment, and safety follow-up phases.
Actively Recruiting
Researchers are investigating the long-term safety of eptinezumab in children and adolescents aged 6 to 17 who have chronic or episodic migraine. This extension study involves participants who completed previous related studies and aims to continue monitoring their response to the treatment over an extended period. The study is phase 3 and evaluates the effects of eptinezumab to better understand its safety profile in this younger population. Participants will receive eptinezumab through intravenous infusions in one of two dose groups 100 mg or 300 mg, both adjusted by weight. Those who received these doses in prior studies will continue the same dose, while those previously on placebo will be randomly assigned to one of the two dose groups with equal chance. Each participant will receive three infusions at weeks 0, 12, and 24 during the open-label extension. Throughout the study, participants will undergo various assessments including tracking of adverse events, blood tests measuring eptinezumab levels and antibodies, and evaluations of migraine disability using the Pediatric Migraine Disability Assessment Questionnaire at specified weeks. The study extends up to week 44, with safety and efficacy monitoring continuing throughout, ensuring comprehensive data collection on the long-term effects of eptinezumab in this age group.
Actively Recruiting
Researchers are evaluating the IntraOsseous BioPlasty4 IOBP4 surgical technique to treat subchondral bone pathology SBP in the knee. This prospective, multicenter clinical study includes both male and female patients aged 18 to 60 years who have symptomatic SBP that has not improved with conservative treatments. The main goal is to assess whether IOBP4 can prevent the need for additional knee surgeries such as knee replacement, high tibial osteotomy, or calcium phosphate stabilization over a five-year period. The study involves subjects receiving the IOBP4 procedure, which includes injecting a biologic mixture of bone marrow concentrate and allograft into the subchondral bone lesion of the knee. Participants are identified from the investigators patient population and must be scheduled for this surgical intervention. This observational study monitors patients over time to evaluate outcomes related to the treatment of SBP. Participants will undergo regular assessments including pain measurement using the Visual Analog Pain Scale at multiple time points from before surgery up to five years after. Knee function and symptoms will be evaluated using the International Knee Documentation Committee Subjective Knee Evaluation Form and the Knee Injury and Osteoarthritis Outcome Score KOOS. Imaging studies such as X-rays and MRI will be performed at six months and one year to monitor the knee condition. Safety monitoring focuses on adverse events and the need for further surgery during the five-year follow-up period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of SPN-817 as an additional treatment in adults with focal onset seizures who have not responded to at least two anti-seizure medications. This Phase 2, double-blind, randomized, placebo-controlled study involves multiple centers and compares SPN-817 to a placebo in adults aged 18 to 70 years taking 1 to 4 anti-seizure medications and experiencing at least four seizures during a six-week screening period. Participants will be randomly assigned in a 21 ratio to receive either SPN-817 3.0 to 4.0 mg twice daily or a placebo. The study includes a titration period lasting 8 to 10 weeks during which an antiemetic medication, ondansetron, is taken prophylactically before each dose to manage potential side effects. After reaching the target dose, participants enter a maintenance period lasting 14 weeks. Ondansetron may be used as needed during this phase. After completing the maintenance period, participants may join a separate open-label study for continued SPN-817 treatment or undergo a tapering period of up to four weeks, followed by a safety follow-up phone call. Throughout the trial, participants will keep electronic seizure diaries, and the research team will monitor seizure frequency and treatment-emergent adverse events. The main measurement is the percent change in seizure frequency during the maintenance period compared to baseline. Additional evaluations include the proportion of participants with significant seizure reduction and seizure-free intervals. The total study involvement includes the screening, titration, maintenance, tapering, and follow-up periods, with assessments to track safety and treatment effects.
1-10 of 13
1